Can Cushing's syndrome cause hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Cushing's Syndrome Cause Hypertension?

Yes, Cushing's syndrome definitively causes hypertension, with blood pressure elevation occurring in 70-90% of patients with this condition 1. This represents one of the most common and clinically significant manifestations of hypercortisolism, contributing substantially to the increased cardiovascular morbidity and mortality seen in these patients.

Prevalence and Clinical Significance

The relationship between Cushing's syndrome and hypertension is well-established across multiple high-quality guidelines. Hypertension prevalence in Cushing's syndrome often exceeds 80% 2, making it a cardinal feature of the disease. The 2018 American Heart Association Scientific Statement emphasizes that glucose abnormalities and hypertension are so common in Cushing's syndrome that the disorder mimics a severe form of metabolic syndrome 2.

The severity of hypertension correlates with both the duration and intensity of cortisol elevation 3. Approximately 17% of Cushing's syndrome patients develop severe hypertension 1, and target organ damage is more severe than in primary hypertension 1.

Pathophysiologic Mechanisms

The primary mechanism driving hypertension in Cushing's syndrome is mineralocorticoid receptor activation by excess cortisol 2, 1, 4. When cortisol levels are elevated, some cortisol escapes deactivation by the 11β-hydroxysteroid dehydrogenase 2 enzyme in the kidney and directly activates mineralocorticoid receptors, leading to increased renal sodium absorption 4.

However, hypercortisolism promotes hypertension through multiple additional pathways 2:

  • Activation of the renin-angiotensin system
  • Sensitization of vasculature to catecholamines
  • Impairment of endogenous nitric oxide bioavailability
  • Alterations in peripheral and renovascular resistance
  • Vascular remodeling 3

Screening Considerations in Hypertensive Patients

While hypertension is common in Cushing's syndrome, Cushing's syndrome is not a common cause of resistant hypertension in the general population 2. A study of 423 individuals with resistant hypertension found no overt cases of Cushing's syndrome 2. This reflects the rarity of the condition rather than a weak association.

Screen for Cushing's syndrome in hypertensive patients who are:

  • Younger than 40 years old (prevalence up to 6.2%) 5
  • Have rapidly evolving hypertension 5
  • Present with an adrenal adenoma (prevalence up to 7.7%) 5
  • Display classic cushingoid features: reddish purple striae >1 cm wide, facial plethora, proximal muscle weakness, easy bruising without trauma, unexplained osteoporosis 6
  • Have multiple features of metabolic syndrome with additional suggestive signs 6

The most discriminatory screening test is late-night salivary cortisol (LNSC), though 1 mg overnight dexamethasone suppression test (1 mg DST) or 24-hour urinary free cortisol (UFC) are acceptable alternatives 5.

Treatment Implications

Given the high cardiovascular risk, guidelines explicitly recognize the importance of aggressively treating hypertension in Cushing's syndrome patients 2.

The most effective antihypertensive agent is a mineralocorticoid receptor antagonist (spironolactone or eplerenone) 1, 4. A recent case report demonstrated significant blood pressure improvement within 4 weeks of adding eplerenone to a patient with refractory hypertension on five other agents 4. This underscores that mineralocorticoid receptor blockade should be a cornerstone of therapy 2.

Standard antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers) may be less effective when used alone 1, though they can be used as adjunctive therapy.

Prognosis After Treatment

Approximately 44% of patients achieve complete remission of hypertension after surgical cure of Cushing's syndrome, while 48% show improvement 7. About 80% experience blood pressure normalization or improvement within 10 days of cure 7, though hypertension persists in approximately 30% of cured patients long-term 3.

Predictors of hypertension remission include:

  • Shorter duration of Cushing's syndrome
  • Younger age
  • Lower baseline body mass index 7

Critical pitfall: Blood pressure should be monitored closely after cure, as approximately half of patients fail to normalize blood pressure by one year post-treatment 7. Antihypertensive medications require ongoing adjustment to prevent cardiovascular complications.

References

5
Research

Hypertension and Cushing's syndrome: hunt for the red flag.

Journal of endocrinological investigation, 2025

6
Guideline

the diagnosis of cushing's syndrome: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2008

Related Questions

Could the patient's hypertension, who is on amlodipine 10 mg and has G6PD deficiency with stress‑related blood‑pressure elevation, be due to Cushing's syndrome?
Given complement C3 176 mg/dL, complement C4 36 mg/dL, negative anti‑Ro, anti‑Sm, and anti‑dsDNA antibodies, erythrocyte sedimentation rate 18 mm/hr, C‑reactive protein 3 mg/L, and treatment with amlodipine 10 mg for hypertension, could these findings be due to Cushing’s syndrome?
In a 29-year-old Black male, 6'5" tall and 315 lb, with normal CBC and CMP, positive ANA RNP antibodies (4.7 U, titer 1:80), hypertension, arm and leg muscle weakness, and brain MRI showing confluent periventricular white‑matter hyperintensities consistent with ischemic leukoencephalopathy, could Cushing syndrome explain these findings, and what is the likely prognosis and chance of recovery?
Can Florinef (fludrocortisone) be used long-term?
How to manage a patient with Cushing's syndrome and Sjogren's syndrome?
What is a J‑pouch (ileal pouch‑anal anastomosis) and how is it created in the rectum?
How should I evaluate and manage a 61-year-old male who had a single episode of hematuria two days ago and now has mild dysuria without other urinary symptoms?
What is the simplified Pulmonary Embolism Severity Index (sPESI), how is it calculated, and how does the score guide management of pulmonary embolism patients?
What are the recommended antibiotics and their dosing regimens for treating an inpatient with a COPD exacerbation?
Which coronary artery is most commonly involved in aortic dissection?
Are the antibiotic guidelines for treating an inpatient COPD exacerbation the same in the United States as those described?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.